program guide - j. spargo • 5invited faculty anthony child, md university of leeds leeds, united...

W W W. I M W 2 0 1 7. O R G • 1

Program Guide

1 6 T H I N T E R N AT I O N A L

2 • 1 6 T H I N T E R N AT I O N A L M Y E L O M A W O R K S H O P

ORGANIZING COMMITTEESundar Jagannath, MD

Shaji Kumar, MDSagar Lonial, MD

Nikhil Munshi, MDNoopur Raje, MD

S. Vincent Rajkumar, MD

UNDER THE AUSPICES OF THE INTERNATIONAL MYELOMA SOCIETY AND ITS BOARD OF DIRECTORS

Jesús San Miguel, MD (President)Nikhil C. Munshi, MD (Vice-President)

Sagar Lonial, MD (Secretary)Angela Dispenzieri, MD (Treasurer)

Kenneth C. Anderson, MD (Immediate Past President)Hervé Avet-Loiseau, MD

Meletios-Athanassios Dimopoulos, MDDouglas Joshua, MD

Shaji Kumar, MDAngelo Maiolino, MD

Maria-Victoria Mateos Manteca, MDGareth Morgan, MD

Hirokazu Murakami, MDDonna Reece, MD

Robert A. Kyle, MD (Honorary Board Member)

SCIENTIFIC PROGRAM COMMITTEESundar Jagannath, MD

Lalit Kumar, MDShaji Kumar, MD

Sagar Lonial, MD, FACPPankaj Malhorta, MD

Nikhil Munshi, MDNoopur Raje, MD

S. Vincent Rajkumar, MD

W W W. I M W 2 0 1 7. O R G • 1

WELCOME MESSAGE

Dear Colleagues and Guests,

It is our distinct pleasure and honor to welcome you to New Delhi for the 16th International Myeloma Workshop!

During this prestigious biannual event, myeloma experts from around the world gather to discuss basic, preclinical and clinical aspects in the biology and treatment of multiple myeloma. The scientific program will include oral presentations, consensus panels, debates on controversial and current arguments, and poster abstracts.

We have an exciting social program planned including a wonderful opening and closing reception that will feature the unique culture and cuisine of India. March is also a great time to visit New Delhi and we hope you take some time before or after the meeting to enjoy the many cultural attractions in the “Golden Triangle.”

Best Regards,2017 IMW Organizing Committee

Noopur Raje, MDShaji Kumar, MDNikhil Munshi, MDSagar Lonial, MDSundar Jagannath, MDS. Vincent Rajkumar, MD


Myeloma WorkshopMyeloma Workshop


Wednesday, 1 March Thursday, 2 March Friday, 3 March Saturday, 4 March

07.00-08.00

07.

00

-18

.00

Po

ster

Vie

win

g

07.00-08.00 AMGEN SPONSORED SYMPOSIUM Reaching New Depths: Targeting MRD and Shifting the Treatment Paradigm

07.

00

-18

.00

Po

ster

Vie

win

g

07.00-08.00 BRISTOL-MYERS-SQUIBB SPONSORED SYMPOSIUM Immunotherapy in Multiple Myeloma: Emerging Strategies

07.00-07.30 IMS General Assembly

07.30-08.30 Selected Oral Abstracts

08.00-09.00

08.00-10.00 Role of Transplantation/ Consolidation and Maintenance in MM

08.00-10.00 Precision Medicine: Genomics and Disease Monitoring

08.30-8.45 Keynote Lecture

08.45-09.30 Consensus Panels

09.00-10.00 09.00-09.10 Opening Ceremony

09.10-09.25 IMS and IMW Introduction



09.30-10.00 Coffee/Tea Break

10.00-11.0010.25-12.00 Precursor Disease States


10.00-10.30 Coffee/Tea Break 10.00-12.00

High Risk Disease10.30-12.00 Non-transplant approaches

10.30-12.00 Related Plasma Cell Disorders

11.00-12.00

12.00-13.00 12.00-1.00 Lunch

12.00-1.00 Lunch

12.00-1.00 Lunch

12.00-1.00 Lunch

13.00-14.0013.00-14.30 JANSSEN SPONSORED SYMPOSIUM Raising the Bar in Multiple Myeloma: Redefining the Landscape with Monoclonal Antibodies

11.30-13.00 TAKEDA SPONSORED SYMPOSIUM Proteasome inhibition: From the vast myeloma landscape to individualized decisions

11.30-13.00 CELGENE SPONSORED SYMPOSIUM Optimizing Immunomodulation for Long-Term Myeloma Disease Control

13.00-13.30 Bart Barlogie and Ken Anderson Awards and Lectures

13.30-14.00 Manging Myeloma with Limited Resources

14.00-15.00 14.00-14.30 Critical Questions for the Next Decade

14.30-14.40 Break

14.30-14.40 Break

14.30-14.40 Break

14.30-14.45 Welcome to Boston 2019

14.40-16.00 Simultaneous Oral Sessions



14.45-15.00 Closing Ceremony and Farewell

15.00-16.00

16.00-17.00 16.00-16.30 Coffee/Tea Break



16.30-18.00 Immuno-Oncology

16.30-18.00 Supportive Care and Side Effect Management

16.30-18.00 Relapsed Multiple Myeloma

17.00-18.00

18.00-19.00 18.00-18.30 Landscape of Current International Trials

18.00-19.00 Poster Session I: Poster Display Presentations Poster Discussion Presentations

18.00-19.00 Poster Session II: Poster Display Presentations Poster Discussion Presentations

18.30-20.00 Welcome Reception19.00-20.00

20.00-23.00 20.00-23.00 Closing Gala Reception

SCH

ED

ULE

AT

-A-G

LAN

CE

W W W. I M W 2 0 1 7. O R G • 3

Wednesday, 1 March Thursday, 2 March Friday, 3 March Saturday, 4 March

07.00-08.00

07.

00

-18

.00

Po

ster

Vie

win

g

07.00-08.00 AMGEN SPONSORED SYMPOSIUM Reaching New Depths: Targeting MRD and Shifting the Treatment Paradigm

07.

00

-18

.00

Po

ster

Vie

win

g

07.00-08.00 BRISTOL-MYERS-SQUIBB SPONSORED SYMPOSIUM Immunotherapy in Multiple Myeloma: Emerging Strategies

07.00-07.30 IMS General Assembly

07.30-08.30 Selected Oral Abstracts

08.00-09.00

08.00-10.00 Role of Transplantation/ Consolidation and Maintenance in MM

08.00-10.00 Precision Medicine: Genomics and Disease Monitoring


08.45-09.30 Consensus Panels

09.00-10.00 09.00-09.10 Opening Ceremony

09.10-09.25 IMS and IMW Introduction




10.00-11.0010.25-12.00 Precursor Disease States


10.00-10.30 Coffee/Tea Break 10.00-12.00

High Risk Disease10.30-12.00 Non-transplant approaches

10.30-12.00 Related Plasma Cell Disorders

11.00-12.00

12.00-13.00 12.00-1.00 Lunch

12.00-1.00 Lunch

12.00-1.00 Lunch

12.00-1.00 Lunch

13.00-14.0013.00-14.30 JANSSEN SPONSORED SYMPOSIUM Raising the Bar in Multiple Myeloma: Redefining the Landscape with Monoclonal Antibodies

11.30-13.00 TAKEDA SPONSORED SYMPOSIUM Proteasome inhibition: From the vast myeloma landscape to individualized decisions

11.30-13.00 CELGENE SPONSORED SYMPOSIUM Optimizing Immunomodulation for Long-Term Myeloma Disease Control

13.00-13.30 Bart Barlogie and Ken Anderson Awards and Lectures

13.30-14.00 Manging Myeloma with Limited Resources

14.00-15.00 14.00-14.30 Critical Questions for the Next Decade

14.30-14.40 Break

14.30-14.40 Break

14.30-14.40 Break

14.30-14.45 Welcome to Boston 2019




14.45-15.00 Closing Ceremony and Farewell

15.00-16.00

16.00-17.00 16.00-16.30 Coffee/Tea Break



16.30-18.00 Immuno-Oncology

16.30-18.00 Supportive Care and Side Effect Management

16.30-18.00 Relapsed Multiple Myeloma

17.00-18.00

18.00-19.00 18.00-18.30 Landscape of Current International Trials

18.00-19.00 Poster Session I: Poster Display Presentations Poster Discussion Presentations

18.00-19.00 Poster Session II: Poster Display Presentations Poster Discussion Presentations

18.30-20.00 Welcome Reception19.00-20.00

20.00-23.00 20.00-23.00 Closing Gala Reception


INVITED FACULTYMB Aggarwal, MD Haematology Centre, Mumbai, India Ghamat Lodge

Sikander Ailawadhi, MD Mayo Clinic Jacksonville, United States

Melissa Alsina, MD Moffitt Cancer Center Tampa, United States

Kenneth C. Anderson, MD Medical Oncology, Boston, United States Dana-Farber Cancer Institute, Harvard Medical School

Herve Avet-Loiseau, MD Unite de Genomique Toulouse, France du Myelome, CHU Rangueil

David E. Avigan, MD Beth Israel Deaconess Boston, United States Medical Center

Ashraf Badros, MD University of Maryland Baltimore, United States Greenebaum Cancer Center

Nizar J. Bahlis, MD University of Calgary Calgary, Canada

Francis Baudi, MD Mayo Clinic Rochester, United States

Jesus Berdeja, MD Sarah Cannon Research Nashville, United States Institute

James Berenson, MD Institute for Myeloma & West Hollywood, Bone Cancer Research, United States

Leif Bergsagel, MD Mayo Clinic Scottsdale, United States

Joan Blade, MD, PhD Hospital Clinic Barcelona, Spain

Mario Boccadoro, MD Myeloma Unit, Division of Torino, Italy Hematology, University of Torino

Lawrence Boise, PhD Emory University, Winship Atlanta, United States Cancer Institute

Ivan Borello, MD John Hopkins School Baltimore, United States of Medicine

Francis Buadi, MD Mayo Clinic Rochester, United States

Michele Cavo, MD Bologna University School Bologna, Italy of Medicine, Seragnoli Institute of Hematology

Mammen Chandy, MD Tata Medical Center Kolkata, India

Ajai Chari, MD Tisch Cancer Institute, New York, United States Mount Sinai School of Medicine

Haiming Chen, MD, PhD Shanghai Jiao Teng University Shanghai, China

Marta Chesi, MD Mayo Clinic Phoenix, United States

W W W. I M W 2 0 1 7. O R G • 5

INV

ITE

D FA

CU

LTY

Anthony Child, MD University of Leeds Leeds, United Kingdom

Wee Joo Chng, PhD National University Singapore, Singapore Health System

Adam Cohen, MD Perelman School of Philadelphia, United States Medicine at the University of Pennsylvania

Raymond L. Tufts Medical Center Boston, United States Comenzo, MD

Faith Davies, MD Myeloma Institute Little Rock, United States

Madhav Yale University New Haven, United States Dhodapkar, MBBS

Meletios National and Kapodistrian Athens, Greece Dimopoulos, MD University of Athens

Angela Dispenzieri, MD Mayo Clinic Rochester, United States

Matthew Drake, MD Mayo Clinic Rochester, United States

Brian Durie, MD Cedars-Sinai Medical Center Los Angeles, United States

Hermann Einsele, MD Department of Medicine 2, Würzburg, Germany University Hospital of Würzburg

Thierry Facon, MD Service des Maladies du Sang, Lille, France Hôpital Claude Huriez

Jean-Paul Fermand, MD Hôpital Saint Louis Paris, France

Mariateresa Fulciniti, MD Dana-Farber Cancer Institute Boston, United States

Gosta Gahrton, MD Karolinska Institute Solna, Sweden

Francesca Gay, MD Myeloma Unit, Division Torino, Italy of Hematology, University of Torino

Morie A. Gertz, MD Mayo Clinic Rochester, United States

Irene Ghobrial, MD Dana Farber Cancer Institute Boston, United States

Hartmut Goldschmidt, University Hospital Heidelberg, Germany MD, PhD Heidelberg

Roman Hajek, MD University Hospital Ostrava Ostrava, Czech Republic and Faculty of Medicine Ostrava

Jean Luc Rene Gauducheau Nantes, France Harousseau, MD Cancer Center

Teru Hideshima, MD Dana-Farber Cancer Institute Boston, United States

Jens Hillengass, MD, PhD University Hospital Heidelberg Heidelberg, Germany

Vania Hungria, MD Irmandade da Santa Casa de São Paulo, Brazil Misericórdia de São Paulo


Sundar Jagannath, MD Mount Sinai Medical Center New York, United States

Andrzej Jakubowiak, University of Chicago Chicago, United States MD, PhD

Doug Joshua, AO Royal Prince Alfred Hospital Woollahra, Australia Institute of Hematology

Prashant Kapoor, MD Mayo Clinic Rochester, United States

Jonathan L. Winship Cancer Institute Atlanta, United States Kaufman, MD of Emory University

Jonathan Keats, PhD TGen Phoenix, United States

Navin Khattry, DM ACTREC (Advanced Centre Navi Mumbai, India for treatment, research and education in cancer), Tata Memorial Centre

Neha Korde, MD Memorial Sloan Kettering New York, United States Cancer Center

Amrita Krishnan, MD CIty Of Hope Cancer Center Duarte, United States

Sigrudur Kristensson, MD University of Iceland Reykjavik, Iceland

Lalit Kumar, MD All India Institute of New Delhi, India Medical Sciences, New Delhi

Shaji Kumar, MD Mayo Clinic Rochester, United States

Robert Kyle, MD Mayo Clinic Rochester, United States

C. Ola Landgren, MD, PhD Memorial Sloan Kettering New York, United States Cancer Center

Jae Hoon Lee, MD Gachon University Gil Hospital Incheon, Korea, Republic of

Xavier Leleu, MD CHU la Miletrie Poitiers, France

Suzanne Lentzsch, Division of Hematology/ New York, United States MD, PhD Oncology, Columbia University

Alexander Lesokhin, MD Memorial Sloan Kettering New York, United States Cancer Center

Nelson Leung, MD Mayo Clinic, Rochester, MN Rochester, United States

Yi Lin, MD, PhD Mayo Clinic Rochester, United States

Jens Lohr, MD, PhD Dana Farber Cancer Institute Boston, United States

Sagar Lonial, MD Emory University Atlanta, United States

Heinz Ludwig, Wilhelminen Cancer Vienna, Austria Univ-Prof. Dr. Research Institute

Hemant Malhotra, MD SMS Medical College & Hospital JAIPUR, India

Pankaj Malhotra, MD PGIMER Chandigarh, India

Thomas Martin, MD University of California San Francisco, United States

W W W. I M W 2 0 1 7. O R G • 7

Maria-Victoria Hospital Universitario Salamanca, Spain Mateos, MD Salamanca

Vikram Mathews, MD Christian Medical College, Vellore, India Vellore

Philip McCarthy, MD Roswell Park Cancer Institute, Buffalo, United States Blood and Marrow Transplant Program

Hari Menon, MD Tate Memorial Hospital Bengaluru, India

Giampaolo Merlini, MD University Hospital Policlinico Pavia, Italy San Matteo,

Joseph Mikhael, MD Mayo Clinic Scottsdale, United States

Constantine Dana-Farber Cancer Institute Boston, United States Mitsiades, MD

Mohamad Mohty, Department of Haematology, Paris, France MD, PhD EBMT Paris study office / CEREST-TC / Saint Antoine Hospital

Philippe Moreau, MD CHU de Nantes, University Nantes, France Hospital Hôtel-Dieu-HME

Gareth Morgan, MD, PhD Myeloma Institute Little Rock, United States

Nikhil Munshi, MD Harvard (Dana Farber) Boston, United States Cancer Institute

Ruben Niesvizky, MD New York Presbyterian New York, United States Hospital-Weill Cornell Medical Center

Ajay Nooka, MD, MPH Winship Cancer Institute Atlanta, United States of Emory University

Elizabeth O’Donnell, MD Massachusetts General Boston, United States Hospital

Enrique Ocio, MD, PhD Hospital Universitario Salamanca, Spain de Salamanca

Robert Orlowski, MD MD Anderson Cancer Center Houston, United States

Christina Panaroni, PhD Mass General Hospital Boston, United States

Hari Parameswaran, MD Medical College of Wisconsin Milwaukee, United States

Samir Parekh, MD Mount Sinai New York, United States

Muzaffar Qazilbash, MD UT MD Anderson Cancer Houston, United States Center

Noopur Raje, MD Massachusetts General Hospital Boston, United States

S.Vincent Rajkumar, MD Division of Hematology, Rochester, United States Mayo Clinic

INV

ITE

D FA

CU

LTY


Prabhal Rao, MD Dana-Farber Cancer Institute Boston, United States

Donna Reece, MD Princess Margaret Hospital Toronto, Canada

Paul Richardson, MD Medical Oncology, Boston, United States Dana-Farber Cancer Institute, Harvard Medical School

G.David Roodman, Indiana University Simon Indianapolis, United States MD, PhD Cancer Center

Jacalyn Rosenblatt, MD Beth Israel Deaconess Boston, United States Medical Center

Laura Rosinol, MD, PhD Hospital Clinic Barcelona, Spain

Tapan Saikia, MD Prince Aly Khan Hospital Mumbai, India

Jesus San Miguel, Clí nica Universidad de Navarra Navarra, Spain MD, PhD

Vaishali Boston University School Boston, United States Sanchorawala, MD of Medicine

Jatin Shah, MD University of Texas MD Houston, United States Anderson Cancer Center

Mala Shanmugam, MD Emory University School Atlanta, United States of Medicine

Atul Sharma, MD All India Institute of Medical New Delhi, India Sciences, New Delhi

Kazuyuki Shimizu, National Hospital Organization Nagoya, Japan MD, PhD Higashi Nagoya National Hospital

David S. Siegel, MD John Theurer Cancer Center, Hackensack, United States Hackensack University Medical Center

Pieter Sonneveld, MD Erasmus MC Cancer Institute Rotterdam, Netherlands

Andrew Spencer, MBBS The Alfred Hospital/MONASH Melbourne, Australia University/Australian Centre for Blood Diseases

Edward Stadtmauer, MD Abramson Cancer Center, Philadelphia, United States University of Pennsylvania

Keith Stewart, MB, ChB Mayo Clinic Phoenix, United States

Evangelos Terpos, National and Kapodistrian Athens, Greece MD, PhD University of Athens, School of Medicine

Anjan Thakurta, MD Celgene Corporation Summit , United States

Steven Treon, MD, PhD Dana-Farber Cancer Institute Boston, United States

Suzanne Trudel, MD, MSc Princess Margaret Cancer Toronto, Canada

W W W. I M W 2 0 1 7. O R G • 9

Centre, University Health Network

Karin Vanderkerken, MD Vrije Universiteit Brussel (VUB) Brussels, Belgium

Subhash Varma, MD PGIMER Chandigarh, India

Ravi Vij, MD Washington University St. Louis, United States School of Medicine

Peter Vorhees, MD Carolinas HealthCare System Charlotte, United States

Ashutosh National Amyloidosis Centre, London, United Kingdom Wechalekar, MD UCL (Royal Free Campus)

Darrell J. White, MD Queen Elizabeth II Health Halifax, Canada Sciences Centre

Jeffrey Wolf, MD University of California, San Francisco, United States San Francisco

Andrew Yee, MD Massachusetts General Boston, United States Hospital Cancer Center

Qing Yi, MD, PhD Cleveland Clinic Cleveland, United States

Elena Zamagni, MD Azienda Ospedaliero- Malpighi, Bologna, Italy Universitaria Policlinico S. Orsola

Jeffrey A. Zonder, MD Karmanos Cancer Institute Detroit, United States

Sonja Zweegman, VU University Medical Center Amsterdam, Netherlands MD, PhD

INV

ITE

D FA

CU

LTY

10 • 1 6 T H I N T E R N AT I O N A L M Y E L O M A W O R K S H O PI• , .• • • • •

I _J-

W W W. I M W 2 0 1 7. O R G • 11

KEY LOCATIONS

I• , .• • • • •

I _J-

GE

NE

RA

L INFO

RM

AT

ION

l Main Sessions – Pullman Hotel, Peacock Ballroom, Ground Floor

l Wednesday – Friday Simultaneous Oral Sessions – Pullman Hotel, Peacock Ballroom and Pride Hotel, Imperial Ballroom (located across the street)

l Poster Displays and Discussions – JW Marriott, Crystal Ballroom

l Electronic Posters – Pullman Hotel, Lower Ground Floor Foyer

l Exhibits – Pullman Hotel, Comeeting Rooms 1-10, Lower Ground Floor

l Lunches/Coffee Breaks – Pullman Hotel, Lower Ground Floor Foyer and Courtyard

l Registration – Pullman Hotel, Peacock Foyer, Ground Floor

l Speaker Ready Room - Pullman Hotel, Comeeting Room 11, Lower Ground Floor Foyer” below Registration

l Closing Reception - The Roseate, New Delhi (shuttle bus service to/from provided)

l Internet Station – Pullman Hotel, Lower Ground Floor and JW Marriott, Crystal Ballroom Foyer

l Charging Station – Pullman Hotel, Peacock Ballroom Foyer and Lower Ground Floor

l Tour/Information Desk – JW Marriott, Crystal Ballroom Foyer

REGISTRATION INFORMATIONREGISTRATION FEES AND INCLUSIONS

Category Onsite Registration Fee

IMS Member $850 USD

Non-Member $1,050 USD

Spouse/Guest $300 USD

Only credit/debit cards may be used for onsite registration. Neither US dollars nor Indian rupees can be accepted for onsite payments.

The registration fee includes the following:●l IMW abstract and education book (The education book is only available electronically at the imw2017.org website).

●l Admission to scientific sessions, poster display, poster discussions, and poster receptions

●l Access to the exhibition area●l Certificate of attendance (non-MDs will be provided with a certificate of participation)

●l Admission to the welcome and closing receptions*●l Lunches, coffee breaks*●l Access to IMW mobile application

*Spouse/guest registrants will receive only the items marked with an asterisk.


REGISTRATION HOURS

Individuals

Tuesday, 28 February 15:00-19:00

Wednesday, 1 March – Friday, 3 March 07:00-18:00

Saturday, 4 March 07:00-13:00

Groups and Exhibitors

Tuesday, 28 February 13:00-19:00

Wednesday, 1 March 07:00-18:00

BADGES

Official meeting badges and meeting materials will be distributed at the counters in the registration area, located at the Pullman hotel on the Ground Floor (lobby level) outside of the Peacock Ballroom. A Photo ID is required to pick up your meeting badge.

All registered delegates, including speakers, sponsors/exhibitors, media and staff, will be given a badge which must be worn in order to be admitted to the scientific sessions and all social functions/meeting activities.

The barcode on the badge stores the following personal information: First Name, Middle Initial, Last Name, Degree, Organization, Address, City, State/Province, Zip, Country, and Email Address. It can be used by exhibitors to register delegates to their booths and to send additional information on their products and services.

WORKSHOP GENERAL INFORMATIONEXHIBIT HOURS

Wednesday, 1 March 12:00-16:30 and 18:30-20:00Thursday, 2 March 10:00-14:00Friday, 3 March 10:00-14:00

HOTEL LIST

The official IMW hotel accommodations include:●l Holiday Inn New Delhi International Airport

●l JW Marriott Aerocity●l LemonTree Premier, Delhi Airport

●l Novotel Hotel●l Pullman Hotel●l Radisson Blu

All hotels are within walking distance of the meeting venue, except the Radisson Blu. Shuttle service is being provided for the Radisson Blu (see page 14 for more information).

W W W. I M W 2 0 1 7. O R G • 13

INFORMATION AND TOUR DESK

For information about the city and available tours, please visit the Information Desk at the JW Marriott, located outside of the Crystal Ballroom.

INTERNET ACCESS

Visit the internet station to complete the meeting evaluation, access email, and print your boarding pass. The internet station is located at the Pullman Hotel on the lower ground floor. This service is complimentary to all IMW delegates from Wednesday, 1 March through Saturday, 4 March.

Complimentary wireless internet access is available inside the meeting space at the Pullman and JW Marriott as follows:Pullman MarriottSSID: PULLMAN SSID: IMW2017Access Code: Delhi2017 No password or access code required

OFFICIAL WEBSITE

www.imw2017.org

PARKING

Parking is available for a fee at the area hotels.

PHOTO/AUDIO RECORDING POLICY

The presentations, slides, and handouts provided during the program are the property of the IMS or used with permission. Delegates may not photograph, videotape, audiotape or otherwise record or reproduce any of the presentations without express written permission from the IMS, presenter, or copyright owner of such materials.

DISCLAIMER

The IMW will have a professional photographer present at the Workshop. Therefore, please note that any photographs and video taken at the Workshop may be used in future IMW/IMS publications, on the IMW/IMS websites, or in other Society materials.

Videotaping

Videotaping or live streaming in any poster session or session room is strictly prohibited.

Audio Recording

Audio recording or live audio in any poster session or session room is strictly prohibited, except by registered members of the media.

GE

NE

RA

L INFO

RM

AT

ION


MEALS, NETWORKING, AND SOCIAL EVENTS

Lunches, coffee breaks, welcome reception and closing reception are included in the registration fee.

Wednesday, 1 March

Coffee and light refreshments

06:30-07:00

Lunch 12:00-13:00

Coffee Break 16:00-16:30

Welcome Reception 18:30-20:00

Thursday, 2 March


06:30-07:00


Lunch 12:00-13:00


Poster Reception 18:00-19:00

Friday, 3 March


06:30-07:00


Lunch 12:00-13:00


Poster Reception 18:00-19:00

Closing Reception 20:00-23:00

Saturday, 4 March


06:30-07:00


Lunch 12:45-13:30

The Welcome Reception will be held at the Pullman Hotel in the Lower Ground Floor Foyer and adjacent outdoor courtyard.

The Closing Reception will be held at the The Roseate. Transportation will be provided between all hotels and the reception venue throughout the evening. Coffee Breaks and Lunch are at Pullman in Lower Ground Floor Foyer and adjacent outdoor courtyard Poster Receptions at JW Marriott

RESTAURANTS

A wide variety of restaurants and coffee shops are available in the Aerocitycomplex. For additional assistance, please visit the Concierge desk in your hotel.

SHUTTLE INFORMATION

All hotels are within walking distance, except for the Radisson Blu. The IMW will provide complimentary shuttle service between the Radisson Blu and the Pullman Hotel. Transfer services will run according to the meeting schedule. Please look for detailed shuttle bus schedule in the Radisson Blu hotel lobby and on the www.imw2017.org website.

For further information about hotel accommodations and shuttle bus service, please visit the Registration Desk at the Pullman located outside of the Peacock Ballroom, or the Information and Tour Desk at the JW Marriott, located outside of the Crystal Ballroom.

W W W. I M W 2 0 1 7. O R G • 15

At Takeda Oncology, we endeavor to deliver novel medicines to patients with

cancer worldwide through our commitment to science, breakthrough innovation

and passion for improving the lives of patients.

This singular focus drives our aspirations to discover, develop and deliver

breakthrough oncology therapies. By concentrating the power of leading

scientific minds and the vast resources of a global pharmaceutical company, we

are finding innovative ways to improve the treatment of cancer.

We’ve built a portfolio of paradigm-changing therapies and a leading oncology

pipeline. Though we’ve made great strides in our fight against cancer, we are

determined to do more – to work harder and to reach higher. We continue to seek

our aspirations with the same passion, agility and entrepreneurial spirit that has

sustained our patient-centric culture and has made us the leaders in oncology that

we are today.

We know that our mission is not a quick or simple one, but we are up for the task:

we aspire to cure cancer.

©2016 Millennium Pharmaceuticals, Inc. All rights reserved.

To learn more, visit us at takedaoncology.com.

@TakedaOncology

WE ASPIRETO CURECANCER.


PULLMAN HOTEL MAPS

GROUND FLOOR

W W W. I M W 2 0 1 7. O R G • 17

HO

TE

L MA

PS

LOWER GROUND FLOOR


JW MARRIOTT MAP

W W W. I M W 2 0 1 7. O R G • 19

PRIDE MAPH

OT

EL M

AP

S

IMPERIAL BALLROOM IS LOCATED ON THE LOWER GROUND FLOOR


Every patient with cancer will face their own unique journey. Along with you, we are committed to helping to redefine that journey. At Janssen Oncology, our dedication lies in developing best-in-class research and solutions to help you and your patients discover everyday moments of victory.

Victories Over Cancer

MKT

-IBR

-IN

-00

20

Johnson & Johnson Private Limited(formerly Johnson & Johnson Limited) with corporate identity number U33110MH1957PTC010928 has its registered office at L.B.S. Marg, Mulund (West),Mumbai - 400 080.Phone: 022-2564441, Website: www.jnjindia.com.This printed material is for private circulation only to Registered Medical Practitioners or Hospitals or Laboratories.No responsibility is assumed by Johnson & Johnson Pvt. Ltd. for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all the contents are expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.Additional information available on requestDate of Printing: January, 2017©Copyright 2017 by Johnson & Johnson Private Limited

W W W. I M W 2 0 1 7. O R G • 21

SCIENTIFIC INFORMATIONABSTRACTS

Abstracts are available electronically through the www.imw2017.org website and through the 16th IMW mobile app. Full app details are available on page 23 of this program guide. All abstracts are numbered to correspond with presentations listed in this program guide.

CONFLICT OF INFORMATION POLICY

The goals of the International Myeloma Workshop (IMW) are to facilitate improved knowledge and understanding of appropriate, personalized therapeutic strategies for assessing and caring for patients with multiple myeloma. The IMW has a fundamental interest in ensuring that its educational content is consistent with these goals.

In accordance with the American Medical Association (AMA), all meeting session co-chairs, speakers, and oral abstract presenters are required to disclose any conflicts they may have in writing prior to the meeting. All poster presenters are required to disclose any conflicts they may have in writing prior to the meeting and display their disclosures on their poster board.

All IMW presenters (including session co-chairs) are asked to disclose to the audience any relationships of the following nature: honoraria, consultant relationships, participation in a speakers’ bureau, stock holdings or options, royalties, ownership of a company or patent, research contracts or grants, and, in some instances, being an official representative of another organization.

Any questions about this policy or concerns regarding disclosures should be directed to the Registration desk at the Pullman Hotel, located in the Peacock Ballroom Foyer.

CONTINUING MEDICAL EDUCATION CME

Accreditation

The scientific program of the 16th International Myeloma Workshop has been reviewed by the American Medical Association and approved for a maximum of 25.5 AMA PRA Category 1 Credits™.

Physicians should only claim credit commensurate with the extent of their participation in the activity. One credit may be claimed for each hour of participation in approved sessions.

SCIE

NT

IFIC IN

FOR

MA

TIO

N


Educational Objectives

Upon completion of this educational activity, participants should be able to:●l Explain the disease biology based on recent data, and how it can impact the diagnosis, risk assessment and treatment of myeloma and related disorders

●l Discuss the nuances of the new diagnostic criteria and risk stratification systems, the concepts behind the recent changes and how to apply it in daily practice

●l Use the newly updated response assessment criteria in myeloma that incorporates the minimal residual testing and its application in clinical practice and in clinical trials, how to interpret and act upon the results.

●l Compare and contrast available therapies and therapeutic combinations for multiple myeloma on the foundation of recent clinical trial data, and integrate this information into the selection of optimal therapy for patients with multiple myeloma.

●l Describe toxicity profiles of multiple myeloma therapies and considerations for individualized treatment regimens based on these toxicities.

●l Discuss the current role of stem cell transplantation, both autologous and allogeneic, in the management of patients with myeloma.

●l Review the recent advances in supportive care of myeloma, management of infections, bone prophylaxis and pain management.

How to Claim Credit/Certificate of Attendance

Credit claim forms will be available at the registration desk, from the AMA Monitor desk, or in your meeting tote bag. Non-physicians may request an AMA-issued certificate of participation. In order to receive credit/participation certificate from the AMA you must complete the claim form, pay the $35 USD processing fee (waived for AMA members), and return the form to the AMA monitor’s desk at the conference or fax/email the form to AMA headquarters after the conference. A credit certificate will be emailed to you within 4 weeks of receipt of the claim form.

If you should have any questions about certificate processing, you may contact the AMA directly ([email protected], phone: 312.464-4669, or fax: 312-464-5129).

EDUCATION BOOK

The education book is only available electronically at the imw2017.org website. Individual invited presentation manuscripts are also linked to the sessions in the mobile app.

W W W. I M W 2 0 1 7. O R G • 23

FREEMAN XPTOUCH

The official audiovisual provider of the meeting, Freeman, will have a technology platform available during the meeting called XPTouch. This platform will allow delegates to view presentations on their laptop, tablet, or mobile device, as well as participate in the interactive sessions. You will be able to access the platform by going to the website URL provided in the session room at the bottom of the screens. Not all sessions will be utilizing this technology. join.fxptouch.com/imw2017

LANGUAGE

The official language of the IMW is English with no simultaneous translation into other languages.

MOBILE APP

Download the “IMW2017” mobile app from the Apple iTunes Store or Google Play.

The IMW 2017 mobile app allows you to access complete Workshop information at your fingertips. Be sure to download the app on your phone or tablet for one-touch access to the following:●l Poster and oral abstracts●l Interactive schedule including the ability to create your own schedule and take notes during sessions

●l Up-to-the-minute Workshop updates●l Speaker and co-chair listing●l Sponsor listing ●l Meeting venue maps

POSTERS

The IMW will feature three poster formats: poster display, poster discussion, and eposters.

Poster Display

JW Marriott, Crystal BallroomThursday and Friday, 07:00-18:00All scientific posters will be on display and available for viewing in the poster hall on Thursday and Friday during the day. Evening poster presentations will occur from 18:00-19:00. Authors are requested to be at their posters during the evening presentation time slots to answer questions about their posters. Light snacks and refreshments will be served.

SCIE

NT

IFIC IN

FOR

MA

TIO

N


Poster Discussion

JW Marriott, Crystal BallroomThursday and Friday, 18:00-19:00A select number of posters have also been selected for poster discussion during the evening poster presentation slots. These poster abstracts are indicated as such with an icon in the poster listing within this program guide. Poster discussion authors present their poster data for three minutes each on large screens located in the poster hall. One screen is dedicated for disease biology posters and one screen is dedicated to therapy and outcome posters.

ePosters

Pullman Hotel, Lower Ground Floor FoyerA select number of posters have been selected for electronic posters. These poster abstracts are indicated as such with an icon in the posting listing within this program guide. There will be viewing stations available Wednesday to Saturday allowing you to peruse these posters at your pace during the Workshop.

SPEAKER READY ROOM

Pullman Hotel, Comeeting Room 11, Lower Ground Floor

Tuesday, 28 February 15:00-17:00 Wednesday, 1 March – Friday, 3 March 06:00-18:00Saturday, 4 March 06:00-13:00

The Speaker Ready Room is available to all invited speakers, co-chairs, and oral abstract presenters.

All speakers should report to the Speaker Ready Room at least four (4) hours prior to the start of the session in which they are speaking.

CHANGES

Parts of the program may be changed without prior notice. Please refer to the meeting mobile app for the most current schedule and speaker information.

W W W. I M W 2 0 1 7. O R G • 25

W W W. I M W 2 0 1 7. O R G • 27

AWARDSThe International Myeloma Society is proud to recognize the following 16th IMW Award Recipients:

Waldenström Award

Meletios A. Dimopoulos, MDUniversity of Athens School of MedicineAthens, Greece

The Waldenström Award (WA) has been given by the IMS at each International Myeloma Workshop (IMW) since 1989. This award is given to outstanding researchers in recognition to their contributions to the myeloma field. The award is named for Professor Jan Waldenström, who was a pioneer in treating blood cancers.

Bart Barlogie Young Investigator Award

Giovanni Palladini, MDUniversity of PaviaPavia, ItalyBiotechnology Research Laboratories and Amyloidosis Research and Treatment CenterFoundation IRCCS Policlinico San MatteoPavia, Italy

In recognition to the outstanding research developed by Dr. Bart Barlogie in the field of multiple myeloma, the IMS Board of Directors established the Bart Barlogie Young Investigator Award. This award is aimed at formally recognizing and stimulating excellence in myeloma research. The Young Investigator Award is given to an investigator under the age of 45 years in recognition of their research in the myeloma field.

AW

AR

DS


ABOUT THE INTERNATIONAL MYELOMA SOCIETY

The International Myeloma Society (IMS) is a professional, scientific and medical society established to bring together clinical and experimental scientists involved in the study of myeloma.

The IMS membership comprises basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

IMS encourages and promotes the study of this expanding field through its biennial International Myeloma Workshop.

To become a member of the IMS, please visit www.myelomasociety.org.

Apply to Host the 18th International Myeloma Workshop

The IMS seeks proposals from interested IMS members to host the 2021 IMW. The deadline for proposals is 1 November 2017. The announcement of venue will be made in January 2018. For more information on the proposal guidelines, please visit www.myelomasociety.org. Questions can also be directed to [email protected].

Ken Anderson Young Investigator Award for Basic and Translational Research

Irene Ghobrial, MDDana-Farber Cancer InstituteHarvard Medical SchoolBoston, Massachusetts, USA

Established by the IMS to honor the seminal contributions of Professor Ken Anderson from bench to bedside translational research, the Ken Anderson Young Investigator Award is given to an investigator under the age of 45 to both recognize and stimulate excellence in myeloma research.

W W W. I M W 2 0 1 7. O R G • 29

ISATUXIMAB An Investigational Agent in Phase 3

OTHER ISATUXIMAB STUDIES ARE ONGOINGCURRENTLY ENROLLING PATIENTS IN

FRANCE, GERMANY, ITALY, SPAIN, GREECE, JAPAN, AND THE UNITED STATES.

For information, contact: [email protected]

Isatuximab is an investigational agent and has not been approved by any regulatory agency worldwide for the uses under investigation.

This literature is intended for dissemination of scientific information on an investigational product. It is not for promotional purposes.

SAR650984 (isatuximab), Lwide, and Dexamethasone in Combination in RRMM Patients

NCT NUMBER: NCT01749969

SAR650984 (Isatuximab) In Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma


SAR650984 (isatuximab) Combined to CyBorD in Newly Diagnosed Multiple Myeloma (MM) Non-Eligible for Transplant


SAR650984 (Isatuximab), Pomalidomide and Dexamethasone in Combination in RRMM Patients Poster Presentation at ASH 2016


Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies


A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma


Isatuximab Single Agent Study in Japanese Relapsed and Refractory Multiple Myeloma Patients


ONCOLOGY PIPELINE

Isatuximab is an investigational anti-CD38 mAb IgG1 monoclonal antibody1

ICARIA — MMA phase 3, randomized, open-label, multicenter study comparing Isatuximab in Combination with Pomalidomide And Low-Dose Dexamethasone veRsus Pomalidomide and Low-Dose Dexamethasone In patients with refractory or relapsed And refractory Multiple Myeloma

Reference: 1. Deckert J, et al. Clin Cancer Res. 2014;20:4574–83.

SAGLB.ONC.16.12.0850a 01/2017


DOWNLOADING THE IMW 2017 MEETING APP IS EASY!

SEARCH: The App Store or Google Play for “International Myeloma Workshop” or scan the QR Code below.

●l Updated Speaker and Event Information●l Receive meeting alerts and communications from the IMW Organizing Committee

●l Build a personalized schedule●l Take notes and download event handout and presentations

●l Participate in interactive sessions and audience polling

W W W. I M W 2 0 1 7. O R G • 31

C

M

Y

CM

MY

CY

CMY

K



PROGRAM

W W W. I M W 2 0 1 7. O R G • 33


PR

OG

RA

M

PROGRAM DAILY SCHEDULEWednesday, 1 March07.00-18.00 Registration Open Pullman, Peacock Ballroom Foyer

09.00-09.10 Opening Ceremony Pullman, Peacock Ballroom

09.10-09.25 IMS and IMW Introduction Pullman, Peacock Ballroom

Jesus San Miguel

09.25-09.55 Keynote Lecture CME Pullman, Peacock Ballroom

Targeting Achilles Heels in Myeloma Kenneth C. Anderson

09.55-10.25 Keynote Lecture CME Pullman, Peacock Ballroom

Hematopoietic stem cell transplantation in India: An odyssey

Mammen Chandy

PRECURSOR DISEASE STATES CME Pullman, Peacock Ballroom

Co-Chairs: Sigrudur Kristensson, Pankaj Malhotra

10.25-10.40 Genetic basis of monoclonal gmopathies P. Leif Bergsagel

10.40-10.55 Biology of Precursor Disease States: Role of microenvironment

Constantine Mitsiades

10.55-11.10 Predictors of disease progression in MGUS and SMM Laura Rosiñol

11.10-11.20 Current trials in Smoldering myeloma Peter Voorhees

11.20-11.30 Point counterpoint: Early intervention is a slippery slope Angela Dispenzieri

11.30-11.40 Point counterpoint: Early intervention is necessary for cure Sundar Jagannath

11.40-12.00 Panel discussion and questions

12.00-16.30 Exhibits Open Pullman, Lower Ground Floor

12.00-13.00 Lunch Pullman, Lower Ground Floor


13.00-14.30 JANSSEN INDUSTRY-SPONSORED

SYMPOSIUM Pullman, Peacock Ballroom

Raising the bar in multiple myeloma: Redefining the landscape with monoclonal antibodies

mAb-based immunotherapy for myeloma: rationale and mechanism of action

Maria-Victoria Mateos

mAbs in the treatment of myeloma: where are we today? Meletios A. Dimopoulos

Future perspectives on the role of mAbs in myeloma patient management

Philippe Moreau

Clinical efficacy assessment in the era of mAbs Jesus San Miguel

14.30-14.40 Break

14:40-16:00 SIMULTANEOUS ORAL SESSION CME Pullman, Peacock Ballroom

Session 1: Genetic Aberrations and Novel Targets Co-Chairs: Teru Hideshima and Karin Vanderkerken

OP-001 Non-overlapping promoter and super-enhancer driven

processes support myeloma cell growth and survival via distinct regulatory axes

Mariateresa Fulciniti OP-002 Integrating Molecular Genetic and Gene Expression

Profiling Allows Stratification of Ultra-High Risk Myeloma Amy Sherborne

OP-003 Increased mutational burden and alterations to DNA

damage repair genes are associated with poor prognosis and sensitivity to PI3K-mTOR inhibitors in multiple myeloma

Muntasir Mamun Majumder

OP-004 Whole-exome sequencing and ultra low pass-whole

genome sequencing of cfDNA and CTCs enable a comprehensive mutational landscape of Multiple Myeloma

Salomon Manier

W W W. I M W 2 0 1 7. O R G • 35

PR

OG

RA

M OP-005 Profiling of miRnome in Multiple Myeloma Gurvinder Kaur

OP-006 Unveiling the biomarker potential of shelterin complex in

myeloma and revealing their role as therapeutic targets Raman Kumar

OP-007 Quantification of proteins from CD138-purified myeloma

cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene expression value

Norma C. Gutierre

14.40-16.00 SIMULTANEOUS ORAL SESSION CME Pride, Imperial Ballroom

Session 2: Initial Therapy and Transplant Co-Chairs: Ajai Chari, Melissa Alsina

OP-008 Post Autologous Transplant (autoHCT)Therapies in

High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STINA :autoHCT followed by Lenalidomide Maintenance(Len)() vs auto HCT and Len and Bortezomib (BZ) and Dexethasone Consolidation Len Maintenance (ACM) vs Tandem autoHCT Len Maintenance;

Amrita Krishnan

OP-009 Bortezomib, Lenalidomide and low-dose dexethasone (VRD)

versus Lenalidomide and low-dose dexethasone (Ld) for newly-diagnosed Multiple myeloma- A Randomized phase III study-Interim Results

Anjali Mookerjee

OP-010 Lenalidomide (LEN) Maintenance Following High-Dose

Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS)

Philip McCarthy


OP-011 Cardio-vascular toxicity in newly diagnosed, transplant-

ineligible multiple myeloma patients treated with Carfilzomib, cyclophosphide and dexethasone: results from an integrated analysis of 3 phase I/II trials.

Roberto Mina

OP-012 Carfilzomib Weekly Plus Melphalan and Prednisone in

Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) Xavier Leleu

OP-013 A Case Control Study of Syngeneic Transplantation Versus

Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson

Chitra Hosing

OP-014 Impact of treatment intensification according to patient

prognosis: a pooled analysis of 3 randomized phase III trials Mattia D’Agostino

16.00-16:30 Coffee/Tea Break Pullman, Lower Ground Floor

IMMUNO-ONCOLOGY CME Pullman, Peacock Ballroom

Co-Chairs: MB Aggarwal, Doug Joshua

16:30-16:40 The immune microenvironment in Plasma Cell Disorders Madhav Dhodapkar

16.40-16.50 Brakes on the Immune system Qing Yi

16.50-17.00 Checkpoint Blockade: Clinical results Ashraf Badros

17.00-17.10 Cellular Therapies including CART Adam Cohen

17.10-17.20 Vaccination Strategies Ajay Nooka

17.20-17.30 Bispecific MoABs Yi Lin

17.30-18.00 Panel Discussion: Future of immune approaches in MM

W W W. I M W 2 0 1 7. O R G • 37

PR

OG

RA

MLANDSCAPE OF CURRENT INTERNATIONAL TRIALS CME Pullman, Peacock Ballroom

Co-Chairs: Mario Boccadoro, Sikander Ailawadhi

18.00-18.10 North America Jatin Shah

18.10-18.20 Europe Xavier Leleu

18.20-18.30 Asia-Pacific Wee Joo Chng

18.30-20.00 Welcome Reception and Pullman, Lower Ground Floor

Exhibits Open

Thursday, 2 March07.00-18.00 Registration Open Pullman, Peacock Ballroom Foyer

07.00-18.00 ePOSTER DISPLAY SESSION Pullman, Lower Ground Floor Foyer

View electronic posters throughout the meeting at display stations.

07.00-18.00 POSTER SESSION I: VIEWING JW Marriott, Crystal Ballroom

07:00-08:00 AMGEN INDUSTRY-SPONSORED SYMPOSIUM Pullman, Peacock Ballroom

Targeting MRD in myeloma

Defining MRD Hartmut Goldschmidt

Clinical value of achieving MRD in MM C. Ola Landgren

Multidrug combinations driving MRD-negativity A. Keith Stewart

ROLE OF TRANSPLANTATION/CONSOLIDATION AND MAINTENANCE IN MM CME Pullman, Peacock Ballroom

Co-Chairs: Gosta Gahrton, Anthony Child, Navin Khattry

08.00-08.15 Autologous Stem Cell Transplantation in 2020 Sundar Jagannath


08.15-08.30 Allogeneic stem cell: Is there a role? Parameswaran Hari

08.30-08.45 Role of tandem SCT in myeloma Michele Cavo

08.45-9.00 Ongoing phase 3 trials in transplant Amrita Krishnan

09.00-9.10 Unanswered questions in transplant Gosta Gahrton

09.10-9.20 Point counterpoint: Consolidation is standard of care Morie A. Gertz

09.20-9.30 Point counterpoint: Maintenance eliminates need for consolidation

Philip McCarthy

09.30-10.00 Panel Discussion

10.00-10.30 Coffee/Tea Break Pullman, Lower Ground Floor

NON-TRANSPLANT APPROACHES CME Pullman, Peacock Ballroom

Co-Chairs: Tapan Saikia, Joan Blade

10.30-10.45 Defining the transplant ineligible patient Nikhil Munshi 10.45-11:00 Initial therapy approaches: Non-transplant today and

tomorrow Donna Reece

11.00-11:15 Goals of therapy in transplant ineligible patients: balancing efficacy and toxicity

Jean-Paul Fermand

11.15-12.00 Waldenström’s Lecture CME Pullman, Peacock Ballroom

Introduction: Robert Kyle



W W W. I M W 2 0 1 7. O R G • 39

PR

OG

RA

M13.00-14.30 TAKEDA INDUSTRY-SPONSORED

SYMPOSIUM Pullman, Peacock Ballroom

Proteasome inhibition: from the vast myeloma landscape to individualized decisions

Introduction Thierry Facon

The malignant plasma cell and beyond Irene Ghobrial

Tackling the intricate biology of myeloma by proteasome inhibition

Robert Orlowski

Tailoring proteasome inhibition: clinical decision making Sonja Zweegman

Conclusions and future directions in proteasome inhibition in MM

Thierry Facon

14.30-14.40 Break

14:40-16:00 SIMULTANEOUS ORAL SESSION CME Pride, Imperial Ballroom

Session 1: Genomics and Disease Evolution Co-Chairs: Lawrence Boise, Roman Hajek

OP-015 Asymptomatic Multiple Myeloma – Molecular Background

of Progression and Prognosis Anja Seckinger

OP-016 Neutral tumor evolution in myeloma is associated with poor

response to therapy David Johnson

OP-017 The Presence of MDS-like Phenotypic Abnormalities (MDS-

PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients With MDS/L-Related Somatic Mutations And Inferior Survival

Bruno Paiva


OP-018 A more mature immunophenotypic make-up of Multiple

Myeloma clone(s) at diagnosis correlates with a higher genomic instability

Marina Martello

OP-019 Evolutionary fitness of relapsed Multiple Myeloma patients

who responded to upfront combination therapy including new drugs

Carolina Terragna

OP-020 Glutine deprivation-elicited sensitization of multiple

myeloma to venetoclax is associated with electron transport chain inhibition.

Mala Shanmugam

OP-021 Integrative Network Analysis Identifies Novel Drivers of

Pathogenesis and Progression in Newly Diagnosed Multiple Myeloma

Samir Parekh

14:40-16:00 SIMULTANEOUS ORAL SESSION CME Pullman, Peacock Ballroom

Session 2: Treatment of Relapsed Myeloma Co-Chairs: Francesca Gay, Muzaffar Qazilbash

OP-022 Oral selinexor shows single agent activity enhanced with PI

or IMID combinations in refractory multiple myeloma (MM) Sagar Lonial

OP-023 A Multicenter, Open-Label, Phase 1b Study of Carfilzomib,

Cyclophosphide, and Dexethasone in Newly Diagnosed Multiple Myeloma Patients (CHPION-2)

Ralph Boccia

OP-024 Phase 1b Study of Daratumumab plus Pomalidomide

and Dexethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy

Ajai Chari

W W W. I M W 2 0 1 7. O R G • 41

PR

OG

RA

M OP-025 ANALYSIS OF THE AVAILABILITY OF ANTI-MYELOMA

DRUGS AND IMPACT ON THE CURRENT MANAGEMENT OF MYELOMA IN LATIN ERICAN COUNTRIES

Roberto Jose Pessoa de Magalhaes Filho

OP-026 A Phase 1b Study of Venetoclax Combined with Bortezomib

and Dexethasone in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau

OP-027 Preliminary Results From a Phase Ib Study of Isatuximab in

Combination with Pomalidomide (Pom) and Dexethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)

Paul Richardson

OP-028 Depth of Response and MRD with Daratumumab Plus

Lenalidomide and Dexethasone (DRd) vs Lenalidomide and Dexethasone (Rd) in RRMM: POLLUX

Jesus San-Miguel


SUPPORTIVE CARE AND SIDE EFFECT MANAGEMENT CME Pullman, Peacock Ballroom

Co-Chairs: Hari Menon, David S. Siegel

16.30-16.45 Proteasome Inhibitor associated toxicities Jacalyn Rossenblatt

16.45-17.00 IMIDS and long term toxicities Joseph Mikhael

17.00-17.15 Bone disease and management of complications Evangelos Terpos

17.15-17.30 Renal disease and management Raymond L. Comenzo

17.30-17.45 Toxicities and clinical issues with immunotherapies Thomas Martin

17.45-18.00 Imaging in Myeloma: What, when and where Jens Hillengass


POSTER SESSION I JW Marriott, Crystal Ballroom

18.00-19.00 Disease Biology and Related Disorders Co-Chairs: Teru Hideshima, Cristina Panaroni, Mariateresa

Fulciniti

18.00-19.00 Therapy and Outcomes Co-Chairs: Elizabeth O’Donnell, Francis Buadi, Jesus Berdeja

Friday, 3 March07.00-18.00 Registration Open Pullman, Peacock Ballroom Foyer

07.00-18.00 ePOSTER DISPLAY SESSION Pullman, Lower Ground Floor Foyer


07.00-18.00 POSTER SESSION II: VIEWING JW Marriott, Crystal Ballroom

07.00-08.00 BRISTOL-MYERS-SQUIBB INDUSTRY-SPONSORED SYMPOSIUM Pullman, Peacock Ballroom

Immunotherapy in Multiple Myeloma: Emerging Strategies

Quick quiz Alexander Lesokhin

Immunotherapy in multiple myeloma (MM): Where we are now

Darrell White

Examining strategies to tailor immunotherapy to the patient with MM

Jeffrey Zonder

Questions from the audience

The biology behind immunotherapy in MM and its implications for the future

Alexander Lesokhin

Applying immunotherapy principles Alexander Lesokhin

prIME Points™ Alexander Lesokhin

W W W. I M W 2 0 1 7. O R G • 43

PR

OG

RA

M Note: This symposium has obtained separate CME for

this activity. For more information, please speak with the symposium staff at the entrance to the ballroom.

PRECISION MEDICINE: GENOMICS AND DISEASE MONITORING CME Pullman, Peacock Ballroom

Co-Chairs: Shaji Kumar and Hemant Malhotra

08.00-08:15 Genomic evolution in myeloma Herve Avet-Loiseau

08.15-08.30 Epigenetic regulation and HDAC inhibitors Enrique Ocio

08.30-08.45 Circulating DNA: clinical applications Suzanne Trudel

08.45-09.00 Single cell sequencing Jens Lohr

09.00-09.10 Platforms for Precision medicine trials Jonathan Keats

09.10-09.20 Point counterpoint: Precision medicine is the future of myeloma

Ravi Vij

09.20-09.30 Point counterpoint: Precision medicine is more hype than reality

Suzanne Lentzsch

09.30-10.00 Panel Discussion and Questions

10.00-10.30 Coffee/Tea Break Pullman, Lower Ground Floor

RELATED PLASMA CELL DISORDERS PEACOCK BALLROOM CME Pullman, Peacock Ballroom

Co-Chairs: Mohamad Mohty, Jae Hoon Lee

10:30-10:50 Amyloidosis: state of the art Giampaolo Merlini

10:50-11:05 Novel experimental approaches in amyloidosis and related plasma cell disorders

Vaishali Sanchorawala

11:05-11:20 Waldenströms Macroglobulinemia: What next? Steven Treon

11:20-11:35 Novel Insights into Bone Disease Biology and Treatment G.David Roodman


11:35-11:50 Monoclonal gammopathies of Renal significance Nelson Leung

11:50-12:00 Uncommon monoclonal gammopathies Ashutosh Wechalekar



13.00-14.30 CELGENE INDUSTRY-SPONSORED SYMPOSIUM Pullman, Peacock Ballroom

Optimizing immunomodulation for long-term myeloma disease control

Welcome and introduction David E. Avigan

Immunologic basis for myeloma therapy Ivan Borello

Insights into molecular mechanisms of IMiDS Anjan G. Thakurta

The role of the immune system and vaccine therapy in multiple myeloma

Gareth Morgan

Myeloma XI; maintenance and clonal evolution David E. Avigan

14.30-14.40 Break

14:40 -16:00 SIMULTANEOUS ORAL SESSION CME Pride, Imperial Ballroom

Session 1: Diagnosis and Risk Stratification Co-Chairs: Neha Korde and Prashant

OP-029 Next Generation Sequencing Based Revised International

Staging System (R-ISS) for Multiple Myeloma Mark Fiala

OP-030 Going off the “Gold-Standard”: Replacing Electrophoretic

Methods with Mass Spectrometry for Plasma Cell Disorders David Murray

W W W. I M W 2 0 1 7. O R G • 45

PR

OG

RA

M OP-031 SLAM family member “CD229”: a novel gating marker for

plasma cells in flow cytometric immunophenotyping (FCI) of multiple myeloma (MM)

Sitar Ghogale

OP-032 Changes in Serum B-Cell Maturation Antigen Levels are

a Rapid and Reliable Indicator of Treatment Efficacy for Patients with Multiple Myeloma

James Berenson

OP-033 Natural history of t(11;14) multiple myeloma Arjun Lakshman

OP-034 Treatment Patterns from 2009-2015 in Patients With Newly

Diagnosed Multiple Myeloma in the United States: A Report From the Connect® MM Registry

Rafat Abonour

OP-035 Incidence of secondary primary malignancies (S) in patients

with multiple myeloma (CALM study) Laurent Garderet

14:40 -16:00 SIMULTANEOUS ORAL SESSION CME Pullman, Peacock Ballroom

Session 2: Related Plasma Cell Disorders Co-Chairs: Matthew Drake, James Berenson

OP-036 Clinical profiles and outcomes in 1203 newly diagnosed

patients with Systemic AL amyloidosis – first analysis of the ALChemy study.

Richa Manwani

OP-037 NEOD001 Demonstrates Organ Biomarker Responses in

Patients With Light Chain amyloidosis and Persistent Organ Dysfunction: Results From a Phase 1/2 Study

Morie A. Gertz

OP-038 Comparison of Haematopoietic Stem Cell Transplantation

Approaches in Primary Plasma Cell Leukaemia Sarah Lawless


OP-039 IMPACT OF EVOLVING PATTERN IN EARLY PROGRESSION OF

PATIENTS WITH SMOLDERING MULTIPLE MYELOMA Carlos Fernández de Larrea

OP-040 Persistence of Minimal Residual Disease by multipareter

flow cytometry can hinder recovery of organ dage in patients with AL amyloidosis

Paolo Milani

OP-041 Long term Outcomes in Monoclonal Gammopathy of Renal

Significance (MGRS) Akhil Khera

OP-042 Role of multicolor flow cytometry in assessing bone marrow

involvement by solitary plasmacytoma Prashant Tembhare


RELAPSED MULTIPLE MYELOMA CME Pullman, Peacock Ballroom

Co-Chairs: Jeffrey Wolf, Vikram Mathews

16:30-16:40 In vitro models for drug development Marta Chesi

16:40-16:50 Novel Drug Targets Nizar J. Bahlis

16:50-17:00 Early Phase Trials of Promise Jonathan L. Kaufman

17:00-17:10 Promising agents in phase 2 trials Ruben Niesvizky

17:10-17:20 Point counterpoint: Combination therapy is essential for management of relapsed Myeloma

Paul Richardson

17:20-17:30 Point counterpoint: Combinations increase cost and toxicity with no term benefit

Jean Luc Harousseau

17:30-18:00 Panel Discussion and Questions

W W W. I M W 2 0 1 7. O R G • 47

POSTER SESSION II JW Marriott, Crystal Ballroom

18.00-19.00 Disease Biology and Related Disorders Co-Chairs: Mala Shanmugam, Samir Parekh, Rao Prabhal

18.00-19.00 Therapy and Outcomes Co-Chairs: Andrew Yee, Francis Buadi, Neha Korde

20:00-23:00 CLOSING GALA RECEPTION The Roseate

Transportation will be provided from all official IMW hotels. IMW delegate badge required for shuttle boarding.

Saturday, 4 March07.00-18.00 Registration Open Pullman, Peacock Ballroom Foyer

07.00-13.00 ePOSTER DISPLAY SESSION Pullman, Lower Ground Floor


07.00-07.30 IMS GENERAL ASSEMBLY Pullman, Peacock Ballroom

SELECTED ORAL ABSTRACTS CME Pullman, Peacock Ballroom

Co-Chairs: Edward Stadtmauer, Kazuyuki Shimizu

07:30-07:45 OP-043 The Multiple Myeloma Genome Project: Development of a

Molecular Segmentation Strategy for Risk Stratification of Multiple Myeloma (MM)

Mehmet Samur

07:45-08:00 OP-044 Phase 3 Study (CLARION) of Carfilzomib, Melphalan,

Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)

Thierry Facon

08:00-08:15 OP-045 Venetoclax as Targeted Therapy for Relapsed/Refractory

Multiple Myeloma Shaji Kumar

PR

OG

RA

M


08:15-08:30 OP-46 An International, Randomized, Double Blind Trial

Comparing Denosumab With Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) With Newly Diagnosed Multiple Myeloma

Noopur Raje

08:30-8:45 Keynote: The Future of Myeloma CME Pullman, Peacock Ballroom

Nikhil Munshi

CONSENSUS PANELS CME Pullman, Peacock Ballroom

Co-Chairs: Brian Durie and Subhash Varma

08:45 - 9:00 Panel 1: Recommendations for diagnostic work up, risk stratification and disease monitoring for MGUS and SMM

Shaji Kumar

09:00 - 9:15 Panel 2: Recommendation for management of special populations and high risk myeloma

Sagar Lonial

09:15 - 9:30 Panel 3: Recommendation for Infection prevention and vaccinations in myeloma

Noopur Raje

09.30-10.00 Coffee/Tea Break Lower Ground Floor Foyer

HIGH RISK DISEASE CME Pullman, Peacock Ballroom

Co-Chairs: Andrew Spencer, Atul Sharma

10:00-10:15 High Risk Biology Co-Chairs: Pieter Sonneveld

10:15-10:30 High Risk Clinical Phenotype Andrzej Jakubowiak

10:30-10:45 Designing Risk adapted clinical trials Hermann Einsele

10:45-11:10 How I treat extramedullary disease and plasma cell leukemia Elena Zamagni

11:10-11:20 Point counterpoint: Risk adapted therapy is the standard of care

Heinz Ludwig

11:20-11:30 Point counterpoint: Risk adapted therapy, just an idea Faith Davies

W W W. I M W 2 0 1 7. O R G • 49

11:30-12:00 Panel Discussion

12:00-13:00 Lunch Lower Ground Floor Foyer

13:00-13:15 Bart Barlogie Award and Lecture CME Pullman, Peacock Ballroom

Chair: Brian Durie

13:15-13:30 Ken Anderson Award and Lecture CME Pullman, Peacock Ballroom

Chair: Brian Durie

13:30-14:00 Managing myeloma with limited resources: Regional experiences CME Pullman, Peacock Ballroom

Lalit Kumar, Haiming Chen, Vania Hungria

14:00-14:30 Critical questions for the next decade CME Pullman, Peacock Ballroom

S.Vincent Rajkumar

14:30-14:45 Welcome to Boston 2019 Pullman, Peacock Ballroom

14:45-14:00 Closing ceremony and farewell Pullman, Peacock Ballroom

PR

OG

RA

M


3rd INTERNATIONAL NURSING PROGRAMORGANIZING COMMITTEE

Chair: Tracy King, RN, MScCharise Gleason, MSN, NP-BCBeth Faiman, PhD, MSN, APRN-BCMonica Morris, RN, MScTiffany Richards, PhD, MS, ANP-BCNileema Sharad Shingade

FACULTY

Tanya BurtonCardiff and Vale Health Board, Cardiff, United Kingdom

Donna Catamero, ANP-BC, OCN, CCRCMount Sinai Medical Center, New York, NY, USA

Beth Faiman, PhD, MSN, APRN-BCCleveland Clinic, Cleveland, OH, USA

Charise Gleason, MSN, NP-BCThe Winship Cancer Institute of Emory University, Atlanta, GA, USA

Matthias Hellberg-Naegele, MScUniversity Hospital Freiburg, Freiburg, Germany

Tracy King, RN, MScRoyal Prince Alfred Hospital, Sydney University, Sydney, Australia

Monica MorrisMyeloma UK, Edinburgh, United Kingdom

Thomas R Osborne, MA, MBBS, MRCP, PhDSt Joseph’s Hospice & King’s College London, United Kingdom

Tiffany Richards, PhD, MS, ANP-BCMD Anderson, Houston, TX, USA

Nileema Sharad ShingadeOncology Nurses Association of India, Delhi, India

W W W. I M W 2 0 1 7. O R G • 51

NU

RSIN

G P

RO

GR

AM

Thursday, 2 March

07.50-08.00 OPEN AND WELCOME Tracy King Nileema Sharad Shingade

SESSION 1: OPTIMIZING OUTCOMES Chairs: Monica Morris and Beth Faiman

08.00 - 08.30 What matters most to people with myeloma? Improving the assessment of QOL in the routine clinical care of myeloma patients

Thomas R. Osborne

08.30-09.00 Opportunities for nurse side effect management: A focus on new generation combination therapies

Charise Gleason

09.00-09.30 When Myeloma Escapes: An overview of extramedullary and CNS disease

Tiffany Richards

09.30-09.45 Break

SESSION 2: ABSTRACT SESSIONChairs: Tiffany Richards and Donna Catamero

09.45-10.00 A Life in Limbo: Findings from a study into the experience of caring for myeloma patients

Monica Morris

10.00-10.15 Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and their Management Strategies: A Need for Clinical Research Priority

Beth Faiman

10.15-10.30 Patient’s Perception of Being Involved in a Myeloma Clinical Trial

Tanya Burton

10.30-10.45 Real World Data of the Impact of first cycle Daratumumab on Multiple Myeloma and Amyloidosis Services

Devanshi Pandit


10.45-11.00 myeNURSE: Development and Use of an e-portal for Nurses to Share Best Practice and Information Resources at the Point of Service

Tracy King

11.00-11.15 Patient Reported Symptom Concerns and Provider Intervention in Patients with Multiple Myeloma

Beth Faiman SESSION 3: MODELS OF CAREChairs: Tracy King and Tanya Burton

11.15-11.45 Screening and Management of Late and Long-term Effects of myeloma and its treatment

Monica Morris

11.45-12.15 Development of an Advanced Nursing Practice role in Myeloma: The German experience

Matthias Hellberg-Naegele

12.15-12.30 CLOSE Tracy King, Nileema Shingade, and Beth Faiman (2019)

W W W. I M W 2 0 1 7. O R G • 53

POSTER SESSION – THURSDAY (d) denotes a poster discussion abstract

DISEASE BIOLOGY AND RELATED DISORDERS

PS-047 Yoshiaki Abe Prevalence and prognostic impact of cytogenetic abnormalities in 220 patients with multiple myeloma

PS-048 (d) Ibrahim Aldoss Acute lymphoblastic leukemia (ALL) as a second primary malignancy (SPM) after multiple myeloma (MM): Secondary clonally related neoplasm or therapy-related leukemia?

PS-049 Gregorio Barilà Infections in Multiple Myeloma: An Underestimate Risk Factor of Comorbidity

PS-050 Krystal Bergin Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM): A report from the MRDR

PS-051 Lenka Besse EDO-S101, an alkylating-HDAC-inhibitor, is synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

PS-052 Andrej Besse Expression of MDR1 Mediates Carfilzomib Resistance in MM and PCL Patients and May be Overcome by HIV Protease Inhibitors Nelfinavir and Lopinavir

PS-054 Arzu Cengiz Association between baseline PET/CT findings and CD38, CD138 expressing myeloma cells in bone marrow and clinical parameters in patients with multiple myeloma

PO

STE

RS


PS-055 Angela Dispenzieri Rapid MALDI-TOF method for detecting and isotyping M-Proteins: evaluation of paired samples of serum and urine in different clinical settings.

PS-056 (d) Mariateresa Fulciniti Splicing factor SRSF1 is dysregulated in multiple myeloma with functional and clinical significance.

PS-057 Saravanan Ganesan Fate of Ikaros in multiple myeloma cells upon treatment with lenalidomide and proteasome inhibitor

PS-058 Nicola Giuliani Bone marrow DKK-1 levels identify patients with smoldering myeloma with higher risk of progression to active multiple myeloma

PS-059 Ritu Gupta Influence of predictor genes of TC classification on clinical outcome in Multiple Myeloma

PS-060 Ritu Gupta Dissecting genetic aberrations in Multiple Myeloma using aCGH and MLPA

PS-061 Liang-Tsai Hsiao Hepatitis B virus reactivation in HBsAg-negative patients with multiple myeloma: cannot be overlooked in the endemic area

PS-062 Jungwon Huh Characteristics of chromosome 17p aberrations identified by metaphase cytogenetics, interphase FISH and sequencing in multiple myeloma

PS-063 Michiko Ichii Suppression of normal B lymphopoiesis in bone marrow induced by myeloma progression.

W W W. I M W 2 0 1 7. O R G • 55

PO

STE

RS

PS-064 Megan Jagosky AUTOLOGOUS STEM CELL TRANSPLANT IMPROVES DEPTH OF RESPONSE AND OUTCOMES IN AFRICAN AMERICAN PATIENTS WHEN COMPARED WITH CAUCASIAN PATIENTS

PS-065 Sung-Hoon Jung The outcomes of Korean patients with primary plasma cell leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)

PS-066 Sung-Hoon Jung A prognostic scoring system for patients with multiple myeloma who were classified stage II by Revised International Staging System

PS-067 Yuta Kaito Serum soluble SLAMF7 is correlated with disease progression in multiple myeloma and may affect anti-SLAMF7 antibody therapy

PS-068 (d) Efstathios Kastritis Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis

PS-069 Tina Bagratuni Indirubins: A Potential Therapeutic Target in Multiple Myeloma

PS-070 Eirini Katodritou Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents

PS-071 Zuzana Kufova Exome sequencing of AL amyloidosis reveals recurrently mutated genes


PS-072 Rajesh Kumar Monoclonal immunoglobulin deposition disease and proliferative glomerulonephritis with monoclonal immunoglobulin disease- how do they differ clinically?

PS-073 Deepesh Lad Evaluating the role of Tregs in the progression of Multiple Myeloma

PS-074 Chrysavgi Lalayanni PROGNOSTIC VALUE OF DIAGNOSTIC BONE MARROW PLASMA CELL PERCENTAGE IN MULTIPLE MYELOMA

PS-075 Violeta Martinez Robles IMWG ´14 DIAGNOSTIC CRITERIA TO INITIATE TREATMENT IN NEW DIAGNOSED MULTIPLE MYELOMA (NDMM): REAL-WORLD STATISTICS

PS-076 Deborah Martinez-Baños Methylation of multiple myeloma in activity and remission

PS-077 (d) Mauricette Michallet Response assignment using Hevylite correlates with clinical outcome in multiple myeloma

PS-078 John Mills A Widely Applicable Method for Resolving Therapeutic Monoclonal Drug Interference for Myeloma Patients

PS-079 Courtney Tate Combination bone marrow imaging using PET-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis

PS-080 Vittorio Montefusco Diarrhea incidence in multiple myeloma patients treated with lenalidomide and pomalidomide

W W W. I M W 2 0 1 7. O R G • 57

PO

STE

RS

PS-081 (d) David Murray High Sensitivity Detection of Residual Disease in Multiple Myeloma from Blood

PS-082 Paola Omedè Heavy+light chain and free light chain assays at baseline and during follow-up in EMN02/HO95 multiple myeloma clinical trial

PS-083 Sasikala P.Sachithanandan HES1, a bHLH transcription factor regulate cell proliferation and promotes apoptosis in in Multiple Myeloma cells

PS-084 Ayyappan Palanisamy EPIDEMIOLOGICAL STUDY OF MULTIPLE MYELOMA –RETROSPECTIVE ANALYSIS FROM A TERTIARY CENTRE

PS-085 Guy Pratt Changes in cytokine production and metabolism in bone marrow mesenchymal stem cells in MGUS and multiple myeloma are driven by hypoxia induced PADI2 expression altering the transcriptome

PS-086 Elizabeta de los Angeles Comprehensive analysis of transcript Rojas Ricardo isoforms in primary plasma cell

leukemia and multiple myeloma with del(17p) showed significant differences between both dyscrasias

PS-087 (d) Eric Sanchez Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 in Combination with Active Myeloma Agents In Vitro and In Vivo

PS-088 Natalia Schutz IMPACT OF FRAILTY ON OVERALL SURVIVAL OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA


PS-089 Masood Shammas Stabilization of ATRIP by SHFM1 regulates homologous recombination and genome stability in myeloma

PS-090 Faye Sharpley 18FDG-PET positivity post radiotherapy is a biomarker for relapse in patients with plasmacytoma

PS-091 Sneha Sisodiya Flow cytometric immunophenotyping in lymphoplasmacytic lymphoma/Waldenstrom’s Macroglobulinemia demonstrates characteristic antigen expression pattern

PS-092 Yutaka Tsukune Hepatitis B virus reactivation in multiple myeloma patients in the era of novel agents: a nationwide retrospective study in Japan

PS-093 Shuling Li Mortality by Frailty Status as Defined by a Claims-Based Disability Status in Elderly Patients Newly Diagnosed with Multiple Myeloma in the United States

PS-094 Arun Wiita Hijacking myeloma metabolism to target cytotoxic chemotherapy to malignant plasma cells with decreased bone marrow toxicity

PS-095 Zhigang Xie REIIBP is a Histone Methyltransferase Overexpressed in T(4;14) Multiple Myeloma with Oncogenic Potential

PS-096 Uday Yanamandra AYA-MYELOMA: REAL WORLD, SINGLE CENTER EXPERIENCE OVER LAST 5 YEARS

W W W. I M W 2 0 1 7. O R G • 59

PO

STE

RS

PS-097 Candice Yong Treatment Patterns and Outcomes in Clinical Practice Among Patients with Newly-Diagnosed Multiple Myeloma: Systematic Literature Review

PS-098 Candice Yong Rates and Predictors of Stem Cell Transplant in Elderly Medicare Beneficiaries with Multiple Myeloma in the United States

PS-099 Mark Fiala The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

THERAPY AND OUTCOMES

PS-100 (d) Mark Fiala A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone [CDD] for Relapsed or Refractory Multiple Myeloma

PS-101 Martin Štork Repeated lenalidomide treatment in patients with relapsed multiple Myeloma

PS-102 Shohei Andoh Efficacy and safety of VTD-PACE regimen in relapsed or refractory multiple myeloma

PS-103 Belen Ballina VTD IN OLDER PATIENTS COMPARATIVE WITH YOUNGER

PS-104 Belen Ballina COST-EFFECTIVENES OF AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN OVER 65 YEARS NEW DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS


PS-105 Jesus Berdeja Efficacy and Safety of Once-Weekly Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the CHAMPION-1 Study by Prior Lines of Therapy

PS-106 (d) Sara Bringhen CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA PATIENTS: A MULTICENTER, OPEN LABEL PHASE 1/2 STUDY

PS-107 Taylor Brown TOWARDS RESPONSE-ADAPTIVE CHANGES IN INDUCTION THERAPY TO IMPROVE SURVIVAL OUTCOMES IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

PS-108 David Cairns From plateau to MRD-negative CR: outcomes in the MRC/NCRI series of randomised trials in newly diagnosed patients with multiple myeloma from 1980 to 2016

PS-109 Claudio Cerchione BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE

PS-110 Manik Chatterjee A phase I/IIa study of the CD38 antibody MOR202 in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma

PS-111 Francesco Di Raimondo European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM)

W W W. I M W 2 0 1 7. O R G • 61

PO

STE

RS

PS-112 Meletios Athanasios Outcomes of Consecutive Patients Dimopoulos With Newly Diagnosed Myeloma

Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival

PS-113 Meletios Dimopoulos Efficacy and Safety of Daratumumab-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma – A Systematic Literature Review and Network Meta-analysis

PS-114 (d) Thierry Facon Final Survival Analysis From the FIRST Trial: Lenalidomide Plus Low-Dose Dexamethasone Until Progression (Rd Cont) v Melphalan, Prednisone and Thalidomide (MPT), and Rd for 18 Cycles (Rd18) for Transplant-Ineligible (TNE) Patients (Pts) With Newly Diagnosed Multiple Myeloma

PS-115 Gisela Ferreira Elevated neutrophil-to-lymphocyte ratio at Day+100 is associated with decreased progression-free survival after hematopoietic stem cell transplantation in multiple myeloma

PS-116 Barbara Gamberi European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT)

PS-117 Maria Gavriatopoulou Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL amyloidosis treated with Bortezomib


PS-118 Luisa Giaccone Upfront Tandem Auto-Allo Transplant in Multiple Myeloma: long-term follow-up and impact of “new drugs” at relapse

PS-119 Jian Hou Improved PFS and OS with ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Final data from the phase 3 China continuation of TOURMALINE-MM1

PS-120 Victor Jimenez-Zepeda Daratumumab for the treatment of Relapsed/Refractory Multiple Myeloma: A single center experience

PS-121 Victor Jimenez-Zepeda Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) compared to Lenalidomide and Dexamethasone (LD) for the treatment of non-transplant eligible MM

PS-122 Nisha Joseph Safety and Engraftment Parameters for Bloodless Transplants among Myeloma Patients

PS-123 Ki Sun Jung Analysis of efficacy and predictive factors for treatment response of thalidomide-containing regimens in patients with relapsed/refractory multiple myeloma who have received prior chemotherapy including bortezomib and lenalidomide

PS-124 Min Kyoung Kim Bortezomib-melphalan-prednisone (VMP) versus MP as initial treatment for very elderly patients with newly diagnosed multiple myeloma

W W W. I M W 2 0 1 7. O R G • 63

PO

STE

RS

PS-125 Justin King The efficacy of salvage autologous stem cell transplant for patients with multiple myeloma who received maintenance therapy post an initial transplant

PS-126 Masato Komuro Relative Dose Intensity (RDI) of Lenalidomide affects the outcome of patients treated with VRD consolidation followed by autologous stem cell transplantation

PS-127 Amrita Krishnan Incidence and timing of Graft versus Host disease (GVHD) after daratumumab (Dara) anti CD38 therapy post allogeneic transplant (alloHCT) for myeloma

PS-128 Jeevan Kumar Single center experience with autologous stem cell transplantation for multiple myeloma: a retrospective analysis

PS-129 Arjun Lakshman Pre-treatment small fiber neuropathy by sympathetic skin response (SSR) does not predict treatment emergent neuropathy in newly diagnosed multiple myeloma (NDMM) patients receiving bortezomib based induction therapy

PS-130 Sarah Lawless Outcome of the rare myeloma subtypes- An analysis of the Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) data

PS-131 Je-Jung Lee Phase 2 study using intravenous busulfan and melphalan conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma; final analysis (KMM150)


PS-132 Hyun-Ju Lee Cytoplasmic transduction peptide-fused recombinant tumor-associated antigens can elicit a potent myeloma-specific cytotoxic T lymphocyte by loading onto dendritic cells

PS-133 Ho Sup Lee The efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP)

PS-134 Heinz Ludwig Ixazomib in combination with thalidomide and dexamethasone astreatment for patients with relapsed/refractory multiple myeloma: An ongoing phase II trial

PS-135 Elias K. Mai Response After Induction Therapy in Transplant-eligible Newly-diagnosed Myeloma - a Pooled Analysis from Three Subsequent Multicenter Phase III Trials

PS-136 Chang Ki Min Low frequency of CD161+CD4+ T cells correlate with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment

PS-137 Soniya Nityanand Comparison of Bortezomib versus non Bortezomib regimens in the treatment of Multiple Myeloma: Experience from a Tertiary Care Centre in North India

W W W. I M W 2 0 1 7. O R G • 65

PO

STE

RS

PS-138 Fuat Oduncu Bisphosphonate induced osteonecrosis of the jaw (BONJ) in patients with multiple myeloma undergoing autologous stem cell transplantation

PS-139 Anand Srinivasan Total dose but not combination of Bortezomib regimen influences outcomes in multiple myeloma

PS-140 Seong Kyu Park Optimal timing of second transplant in myeloma patients without optimal response to first transplant

PS-141 Arun Ramanan Induction therapy and thalidomide based maintenance in multiple myeloma - A retrospective analysis from a tertiary cancer center.

PS-142 Robert Rifkin Global, Prospective, Non-interventional, Observational Study of Disease Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma (MM) Patients (pts): The INSIGHT MM Study (NCT02761187)

PS-143 Dorothy Romanus Triplet Therapy & Overall Survival (OS) in Routine Practice among Transplant-Ineligible Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the United States (US)

PS-144 Dorothy Romanus Treatment (tx) Patterns & Outcomes by Line of Therapy (LOT) in a Large United States (US) Cohort of Transplant-Ineligible Patients (pts) with Multiple Myeloma in the Era of Novel Agents


PS-145 Dorothy Romanus Association Between Treatment Regimen Type in Second-Line Therapy (2LT) and Duration of Therapy (DOT) & Time To Next Treatment (TTNT) in a United States (US) Relapsed/Refractory Multiple Myeloma (RRMM) Cohort

PS-146 Dorothy Romanus Newly Diagnosed Multiple Myeloma (NDMM): Effect of Age, Renal Insufficiency (RI), & Cardiovascular (CV) Disease (dz) on Overall Survival (OS) & Treatment (tx) Patterns Among Stem Cell Transplant (SCT)-Ineligible Patients (pts) in the United States (US)

PS-147 Gunjan Shah Re-immunization following Autologous Hematopoietic Stem Cell Transplantation (auto HCT) is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance

PS-148 (d) Nidhi Tandon Predictors of Early Treatment Failure following initial therapy for Systemic Immunoglobulin Light Chain Amyloidosis

PS-149 Hasib Sidiqi Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma.

PS-150 Aravindh Sivanandsn MULTIPLE MYELOMA STANDARD Anand DOSE VERSUS FIXED DOSE-

A COMPARATIVE STUDY IN TRANSPLANT INELIGIBLE PATIENTS

PS-151 (d) Andrew Spencer Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR

W W W. I M W 2 0 1 7. O R G • 67

PO

STE

RS

PS-152 Michela Staderini Autologous stem cell transplantation in elderly multiple myeloma patients

PS-153 Saad Usmani Case Report: Deep Sustained Response to Daratumumab Associated with T-cell Expansion in a Patient with Heavily Treated Relapsed and Refractory Myeloma

PS-154 Manh-Cuong Vo Dendritic cell vaccination combined with lenalidomide and programmed death-1 (PD-1) blockade has synergistically induced a marked tumor regression in a murine myeloma model

PS-155 Dan T. Vogl Effect of Treatment with Lenalidomide Plus Low-Dose Dexamethasone Until Progression on Health-Related Quality of Life Over Time in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

PS-156 Lianping Xing Development of Bone-Targeted Bortezomib to Treat Multiple Myeloma

POSTER SESSION – FRIDAY (d) denotes a poster discussion abstract

DISEASE BIOLOGY AND RELATED DISORDERS

PS-157 Jithma Abeykoon Outcome of very young (≤ 40 years) patients with immunoglobulin light chain amyloidosis (AL): A case control study


PS-158 Rafat Abonour Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry

PS-159 Belen Ballina IS IT USEFUL THE FOLLOW UP OF MGUS?

PS-160 Arnold Bolomsky High IKAROS expression in bone marrow environmental, but not in myeloma cells predicts for survival with lenalidomide-dexamethasone therapy in myeloma

PS-161 Seila Cerda B2-MICROGLOBULIN (β

2M) IN RENAL

DISFUNCTION PATIENTS. EFFECT IN OVERALL SURVIVAL IN ISS-SUBGROUPS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS

PS-162 Raajit Chanana A retrospective cohort study to evaluate the outcomes of Multiple Myeloma treated in a tertiary care centre from India

PS-163 (d) Gaurav Chatterjee Utility of the new versus old immunophenotypic markers in the flow cytometric immunophenotyping of multiple myeloma

PS-164 (d) Haiming Chen Increase in M2 macrophage polarization in multiple myeloma bone marrow is inhibited with the JAK2 inhibitor ruxolitinib which shows anti-MM effects

W W W. I M W 2 0 1 7. O R G • 69

PO

STE

RS

PS-165 (d) Olena Kis Targeted sequencing of circulating cell-free DNA in multiple myeloma allows analysis of somatic mutations, copy number aberrations, and translocations

PS-166 (d) Mattia D’Agostino Prognostic implication of somatic mutations by next generation sequencing: an analysis from the MMRF CoMMpass study in newly diagnosed multiple myeloma patients.

PS-167 Surendra Dasari Easy to Use Integrated Software for Detection and Isotyping of Monoclonal Gammopathies via MALDI Mass Spectrometry

PS-168 Barbara Dewaele Low-pass sequencing of plasma cell DNA and of ccfDNA for the detection of copy number aberrations and early response monitoring in multiple myeloma

PS-169 Mark Drayson Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test

PS-170 Mark Drayson Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests

PS-171 Ntaganda Fabien Overview of multiple myeloma in Rwanda

PS-172 Despina Fotiou Newly diagnosed multiple myeloma is associated with hypercoagulablity and high risk of VTE. The ROADMAP study


PS-173 Morie A. Gertz Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response

PS-174 Paola Gonzalez EFFECT OF IMPROVEMENTS OF SURVIVAL, POPULATION AGING AND IMWG´14 CRITERIA ON INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA

PS-175 Nidhi Gupta Involvement of a chondroitin sulfate proteolgycan and its correlation with microRNA in bone marrow microenvironment of Multiple Myeloma

PS-176 Ritu Gupta Stain Color Normalization and Segmentation of Plasma Cells in Microscopic Images as a Prelude to Development of Computer Assisted Automated Disease Diagnostic Tool in Multiple Myeloma

PS-177 Ritu Gupta Immunophenotyping Patterns of Plasma cells in Plasma Cell Proliferative Disorders

PS-178 Ana B. Herrero Targeting ongoing DNA damage in multiple myeloma. Effects of different inhibitors of the DNA damage response on plasma cell survival

PS-179 John Jones The Impact of Maintenance Lenalidomide and Depth of Response on the Mutational Status of the Myeloma Clone from Presentation to Relapse

W W W. I M W 2 0 1 7. O R G • 71

PO

STE

RS

PS-180 Shweta Kedia Absolute lymphocyte count and ratio of absolute lymphocyte count/absolute monocyte count (ALC/AMC) provides a readily available prognostic indicator in multiple myeloma

PS-181 Mika Kijima Phenotypic analyses of NK cells in patients with multiple myeloma

PS-182 Taxiarchis Kourelis Characterizing the amyloidogenic protein in patients progressing to light chain amyloidosis from asymptomatic precursor states using mass spectrometry

PS-183 Albana Lico Hyperammonemic encephalopathy as initial presentation of Multiple Myeloma

PS-184 Violeta Martinez Robles SUBCUTANEOUS BORTEZOMIB IN OLDER MULTIPLE MYELOMA PATIENTS (> 75 y/o)

PS-185 Mauricette Michallet Polyclonal immunoglobulin recovery is enhanced after autologous stem cell transplant and associates with improved clinical outcomes in multiple myeloma patients

PS-186 (d) Paolo Milani Glycosylation of immunoglobulin light chains is associated with amyloidosis

PS-187 Vittorio Montefusco Prevalence of ocular disorders in multiple myeloma

PS-188 Elizabeth Moore Maturing data from the Australia and New Zealand Myeloma and Related Diseases Registry


PS-189 Vinod Patil Ten year data of multiple myeloma patients treated at a tertiary care centre in western India

PS-190 Raja Pramanik POEMS syndrome: a Clinical experience of 48 patients and comparative analysis of consolidation ASCT versus non-ASCT cohorts.

PS-191 Guy Pratt Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments

PS-192 Laura Rosiñol Plasmacytomas in multiple myeloma: 45-years experience from a single institution.

PS-193 Daeun Ryu Transcriptional programs associated with extra-medullary tumor progression in multiple myeloma

PS-194 Surinder Sahota Defining clonal plasticity using whole exome sequencing in single cells in an index case of amp1q21 multiple myeloma

PS-195 Alicia Senin COMPARATIVE STUDY OF 18F-FDG-PET-CT AND MAGNETIC RESONANCE IN THE DIAGNOSIS OF SMOLDERING MYELOMA AND BONE PLASMOCYTOMA

PS-196 Ahmed Mohamed Length of Hospital Stay is an Abdel Shafi independent Predictor of Overall

Survival in Patients with systemic AL amyloidosis

PS-197 Lucie Brozova Novel approach to study relationship between copy number variation and gene expression in multiple myeloma

W W W. I M W 2 0 1 7. O R G • 73

PO

STE

RS

PS-198 Torsten Steinbrunn RalA and RalB are potential therapeutic targets in multiple myeloma which mediate cell survival independently of oncogenic RAS

PS-199 Mika Sunakawa Clinical impact and possible immunosuppressive function of soluble B7-H1 (PD-L1) in multiple myeloma

PS-200 Lorenza Torti Immune paresis in treated Multiple Myeloma involving adaptive as well as innate immunity: monocentric experience of 120 patients with serious infectious complications retrospectively analyzed.

PS-201 Chrysanthi Vadikoliou Secondary malignancies in patients undergoing autologous hematopoietic cell transplant for multiple myeloma

PS-202 Patrick Vanderboom Top-Down Immunoglobulin Light chain Sequence Determination in Patients with POEMS Syndrome

PS-203 Uday Yanamandra COMMON REASONS FOR CHANGE OF CHEMOREGIMENS IN MULTIPLE MYELOMA: REAL WORLD, SINGLE CENTER EXPERIENCE

PS-204 Uday Yanamandra Is 18F-FDG-PET/CT a good MRD marker in patients with multiple myeloma? Comparison and correlation with biochemical markers/ flow cytometry.

PS-208 Dorothy Romanus Prevalence and Predictors of Treatment Among Newly Diagnosed Symptomatic Multiple Myeloma (NDMM) Medicare Beneficiaries in the U.S.


PS-210 Victor Jimenez-Zepeda Absolute Lymphocyte Count and Immunoparesis: Impact on clinical outcomes for non-transplant eligible MM patients

PS-205 Meletios Athanasios Oligosecretory and non-secretory Dimopoulos multiple myeloma: Incidence,

Clinical characteristics and Outcomes

THERAPY AND OUTCOMES

PS-206 Meletios Athanasios Prior Lenalidomide Resistance and Dimopoulos the Impact of IMiD-free interval in

patients treated with Pomalidomide and Dexamethasone

PS-207 (d) Meletios Dimopoulos Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX

PS-209 Dorothy Romanus Predictors of Treatment (tx) with Triplet First-Line Therapy (1LT) among Transplant-Ineligible Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) in Routine Clinical Care

PS-211 Victor Jimenez-Zepeda Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) induction followed by ASCT with Bor-HDM conditioning regimen: A single center experience

PS-212 Renato Zambello Diffusion Weighted Whole Body MRI for evaluation of early response in Multiple Myeloma

PS-213 Mukul Aggarwal Second Stem Cell Transplant in Multiple Myeloma: 15 year data from transplant centre from India

W W W. I M W 2 0 1 7. O R G • 75

PO

STE

RS

PS-214 Dhwani Almaula Survival Outcomes of Younger (≤ 50 years) Myeloma Patients

PS-215 Marc-A. Baertsch Efficacy and Tolerability of the Histone-Deacetylase Inhibitor Panobinostat in Clinical Practice

PS-216 Marc-A. Baertsch High cut-off hemodialysis combined with bortezomib-based therapy in multiple myeloma patients with severe renal impairment

PS-217 Krystal Bergin Early Bortezomib Failure Predicts Shorter PFS: A retrospective analysis from 4 tertiary centres in Victoria, Australia

PS-218 David Cairns The impact of thalidomide, zoledronate and high-dose therapy with autologous stem cell support on patient reported outcomes in multiple myeloma: Results of the quality of life substudy of the MRC Myeloma IX randomised controlled trial

PS-219 Claudio Cerchione Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience

PS-220 Yuan Chen SUMOylation and c-Myc Form Feed-Forward Loop Via miR-34b/c Targeted Gene Expression Program

PS-221 Faouzi Djebbari Proteasome inhibitor based induction improves outcomes only in transplant eligible NDMM patients

PS-222 Antonio Garcia Guiñon Long-term reversibility analysis of peripheral neuropathy in multiple myeloma patients treated with Bortezomib.


PS-223 Laurent Garderet Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

PS-224 Laurent Garderet Late vs Early Response and Depth of Response Are Associated with Improved Outcomes: Post-hoc Analysis of Phase 3 TOURMALINE-MM1 Trial (NCT01564537) in Relapsed/Refractory Multiple Myeloma (RRMM)

PS-225 Francesca Gay A Multicenter phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma.

PS-226 Anant Gokarn High dose chemotherapy with autologous stem cell transplantation for multiple myeloma: Outcomes at Tata Memorial Centre.

PS-227 Hartmut Goldschmidt Lenalidomide and low-dose dexamethasone for treatment ofrelapsed/refractory multiple myeloma: real-world treatment patterns from the PREAMBLE study

PS-228 Sundar Jagannath Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data

PS-229 Ellen Jenner The Effect of Clinically Relevant Concentrations of Daratumumab on the Performance of Freelite® Immunoassays

W W W. I M W 2 0 1 7. O R G • 77

PO

STE

RS

PS-230 Raquel Jiménez Efficacy of novel agents on soft-tissue plasmacytomas in patients with relapsed multiple myeloma

PS-231 Jae-Cheol Jo Clinical features and results of bortezomib-melphalan-prednisone (VMP) as initial treatment in elderly multiple myeloma patients received lenalidomide with dexamethasone (Len/Dex): Subgroup analysis of lenalidomide registry from Korean Multiple Myeloma Working Party (KMM151)

PS-232 Sung-Hoon Jung A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma

PS-233 Annette Juul Vangsted Drug response prediction in high risk multiple myeloma

PS-234 Eirini Katodritou REAL-WORLD DATA FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH LENALIDOMIDE AND DEXAMETHASONE IN 2ND LINE (LEGEND STUDY): THE PROGNOSTIC SIGNIFICANCE OF BIOCHEMICAL VERSUS CLINICAL RELAPSE

PS-235 (d) Shaji Kumar Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

PS-236 Sarah Larson Copanlisib has activity as a single agent and in combination with carfilzomib and response correlates with phospho-S6 level


PS-237 Yoo Jin Lee No Relationship between Delta Neutrophil Index (DNI) and Hospitalization in elderly Patients with Newly Diagnosed Multiple Myeloma

PS-238 (d) Suzanne Lentzsch Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR

PS-239 Huamao Mark Lin Real-World Treatment Patterns in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Chart Review in the United Kingdom

PS-240 Huamao Mark Lin Real-World Treatment Patterns and Health Care Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Chart Review in France

PS-241 Tânia Maia TOXICITY AND BENEFIT OF AUTOLOGOUS STEM CELLTRANSPLANTATION IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA

PS-242 (d) Philip McCarthy Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment Crossover in the CALGB/ECOG 100104 (Alliance) Study of Lenalidomide (LEN) Versus Placebo (PBO) Maintenance After Stem Cell Transplant (SCT) for Patients With Newly Diagnosed Multiple Myeloma

PS-243 Yotaro Motomura Double autologous stem cell transplantation followed by maintenance therapy conquers the adverse cytogenetic abnormalities in newly diagnosed multiple myeloma patients

W W W. I M W 2 0 1 7. O R G • 79

PO

STE

RS

PS-244 Chandran Nair Impact of Early Reduction in Paraprotein on Survival in Transplant Ineligible Myeloma : Lesson from a tertiary centre in rural India

PS-245 Eftychia Nikolaou VALIDATION OF FRAILTY ASSESSMENT IN MULTIPLE MYELOMA (MM) PATIENTS

PS-246 Ajay Nooka RVD is a superior induction regimen compared to VCD among transplant-eligible myeloma patients

PS-247 Fotios Panitsas To Treat or not to Treat: Hyperelderly Multiple Myeloma

PS-248 Muzaffar Qazilbash Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation

PS-249 Paul Richardson A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF ISATUXIMAB (SAR650984) PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) VERSUS POM AND DEX IN RRMM

PS-250 Vivek Roy Influence of obesity on outcomes of patients with relapsed refractory multiple myeloma

PS-251 Gunjan Shah Improvement of Response for Multiple Myeloma patients onLenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT).

PS-252 (d) Surbhi Sidana Bortezomib Versus Non-Bortezomib Based Initial Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis


PS-253 David S. Siegel Phase 2 Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Following Second-Line Lenalidomide (LEN)-Based Treatment (Tx) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): An Updated Analysis of Efficacy and Safety

PS-254 (d) David S. Siegel Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

PS-255 Naoki Takezako Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

PS-256 Evangelos Terpos RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study

PS-257 Evangelos Terpos Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study

PS-258 Chrissy H.Y. van Systematic Literature Review and Beurden-Tan Network Meta-Analysis of Treatments

for Relapsed/Refractory Multiple Myeloma Patients

W W W. I M W 2 0 1 7. O R G • 81

PO

STE

RS

PS-259 Katja Weisel Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis

PS-260 Ella Willenbacher Use of the Hevylite™ assay as an early predictive tool in MGUS and smoldering myeloma transformation, as well as myeloma relapse: Results from the EU FP7 project OPTATIO

PS-261 Dr. Neha Yadav Autologous stem cell transplant in Multiple Myeloma: 15 year data from cancer hospital

PS-262 Seoyun Yang Synergistic antitumor immunity by dendritic cells in combination with pomalidomide and dexamethasone in a murine myeloma model

ELECTRONIC POSTERSDISEASE BIOLOGY AND RELATED DISORDERS

E-263 Katharina Lisenko Lymphocytes Characterization in Patients with IgM Monoclonal Gammopathy

E-264 Dibyendu De A CLINICO PATHOLOGICAL PROFILE ANALYSIS OF POEMS SYNDROME A SERIES OF 5 CASES

E-265 Tulin Firatli Tuglular 18F-FDG PET/CT findings and baseline clinical parameters in multiple Myeloma


E-266 Mercedes Gironella Use of 18-F FDG PET / CT scanning into the first follow up of patients with multiple myeloma and association with biochemical response

E-267 Ja Min Byun Impact of chromosomal aberrations detected by FISH on benefits of autologous stem cell transplantation in multiple myeloma patients

E-268 Maria-Veronica Teleanu Gamma heavy chain disease-two new cases with distinct clinical features

E-269 Eugenia Abella Incorporation of a nurse Case Manager for the diagnosis and follow up of patients with multiple myeloma

E-270 Mukesh Barange Synchronous Presentation of Smoldering Multiple Myeloma (SMM) and PolycythemiaVera (PV)-A Rare Case Report

E-271 Swe Mar Linn Case Report: 2 Cases of Rare And Aggressive Plasma Cell Leukemia

E-272 Seila Cerda MULTIPLE MYELOMA (MM) AND PURE RED CELL APLASIA (PRCA): INTERESTING DIAGNOSTIC AND THERAPEUTIC CHALLENGE

TREATMENT AND OUTCOMES

E-273 Shailesh Bamborde Cost- effective Autologous Stem-Cell Transplantation in Plasma cell disorder: Single Institution Experience. Dr Shailesh Bamborde Dr Chandrakala S Dr Farah Jijina

E-274 Swe Mar Linn Myanmar Experience of Clinical Response of Patients With Newly Diagnosed Symptomatic Multiple Myeloma Treated with Bortezomib Based or Non-Bordezomib Based Therapy

W W W. I M W 2 0 1 7. O R G • 83

PO

STE

RS

E-275 Sharat Damodar ASSESSMENT OF QUALITY OF LIFE IN MYELOMA PATIENTS POST AUTOLOGOUS STEM CELL TRANSPLANT- A SINGLE CENTRE EXPERIENCE IN SOUTH INDIA

E-276 Akanksha Garg Isolated Gastrointestinal Graft versus Host Disease after Autologous Hematopoietic Stem Cell Transplantation in a patient of Multiple Myeloma

E-277 Ashwani Kumar Monoclonal Gammopathy Triggering C3 Glomerulopathy: A Rare Association

NURSE SYMPOSIUMNP-284 Tanya Burton CREATING A QUALITY OF LIFE

CLINIC FOR MYELOMA PATIENTS

NP-285 Joseph Tariman Decision Aids Utilized by Patients and Clinicians During Treatment Decision Making for Multiple Myeloma: An Integrative Review

NP-286 Donna Catamero Nursing implications for patients with relapsed and/or refractory multiple myeloma receiving combination therapy with daratumumab (Darzalex™) and lenalidomide.

NP-287 Michaela Hillengass Physical exercise habits of patients with multiple myeloma

NP-288 Faiman, B. Symptom Management and Adherence in Multiple Myeloma (MM): A Plan to Disseminate Best- Practice Guidelines for Nurses


ABSTRACT REVIEWERS

Melissa Alsina, MDJesus Berdeja, MD

James Berenson, MDLarry Boise, MD

Francis Buadi, MDAjai Chari, MD

Dharminder Chauhan, MDMatthew Drake, MD

Mariotteresa Fulciniti, MDFrancesca Gay, MDRoman Hajek, MD

Teru Hideshima, MDPrashant Kapoor, MD

Neha Korde, MDElizabeth O’Donnell, MDChristina Panaroni, MD

Samir Parekh, MDRao Prabhala, MD

Muzaffar Qazilbash, MDMasood Shammas, MDMala Shanmugam, MD

Taimur Sher, MDKazuyuki Shimuzu, MDEdward Stadtmauer, MDKaren Vanderkerken, MD

Andrew Yee, MD

Acknowledgements

PLATINUM SPONSORS

GOLD SPONSORS

ADDITIONAL SUPPORT PROVIDED BY

SILVER SPONSOR

Pantone166 C

Pantone2144 C

Pantone2007 C


International Myeloma Workshopc/o SPARGO, Inc.

11208 Waples Mill Road, Suite 112Fairfax, VA 22030

Phone: 888-788-1522 or 703-449-6418Email: [email protected]

Website: www.imw2017.org

program guide - j. spargo • 5invited faculty anthony child, md university of leeds leeds, united...

Documents